Vizz™, an aceclidine-based eye drop for presbyopia in adults, has been made available by LENZ Therapeutics.
Vizz eye drops contain a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends focus depth to improve vision in presbyopia. The approval was supported by data from two phase 3 trials demonstrating improvement in near vision within 30 minutes after administration lasting up to 10 hours.
The recommended dosage is 1 drop in each eye, followed by a second drop in each eye, after 2 minutes, from the same single-dose vial once daily. Contact lenses should be removed prior to the instillation of the ophthalmic solution and may be reinserted 10 minutes after. If more than 1 ophthalmic product is being used, administer at least 5 minutes apart.
Vizz is supplied as a preservative-free ophthalmic solution containing 1.44% of aceclidine in a single-dose vial. The carton contains 5 foil pouches each with 5 single-dose vials. The product should be stored in the refrigerator; once a pouch or vial is removed from the refrigerator, it may be stored at room temperature but must be used within 30 days.
According to the Company, professional product samples are currently being distributed to eye care professionals nationwide. Commercial shipments will begin in October and broad availability through retail pharmacies is expected by the middle of the fourth quarter of 2025.
This article originally appeared on MPR
References:
LENZ Therapeutics announces commercial product availability of Vizz™ in the United States. News release. LENZ Therapeutics. September 30, 2025. https://www.multivu.com/lenz-therapeutics/9355851-en-lenz-therapeutics-vizz-presbyopia-treatment.
Vizz. Package insert. Lenz Therapeutics; 2025. Accessed September 30, 2025. https://www.vizz.com/full-prescribing-information.pdf.